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Abstract
Objective: Immunosuppressive agents have been proposed to reduce neointimal hyperplasia in synthetic vascular grafts. Thus, the purpose
of the present study was to evaluate the safety and ef®cacy of rapamycins (systemic vs. local vs. oral administration) and mycophenolate
mofetil (MMF) to reduce intimal hyperplasia in infrarenal synthetic vascular grafts of the rat. Methods: Fifty-four Wistar rats (250 g)
completed the study after a synthetic vascular graft (ePTFE, Gore-tex, 2 mm diameter, 10 mm length) was implanted end-to-end in the
infrarenal aorta. The animals were divided into three groups: group 1 consisted of 12 control animals, group 2 consisted of 37 rats receiving
rapamycins, either per os (RAD, 1.5 or 3 mg/kg), intraperitoneally (RPM, 1.5 or 3 mg/kg) or locally (RPM soaking of the graft); and in group
3 (n  5), MMF (40 mg/kg) was administered orally. The animals were followed weekly with weight controls and signs of toxicity for 30
(n  37) and 60 (n  17) days, respectively. All animals were sacri®ced and underwent histological examination at completion of the study.
Results: All animals survived in groups 1 and 3, but ®ve died in group 2. The weight gain was normal in all groups, except for the subgroup
2a receiving high dose rapamycins orally. All rats in group 3 suffered from diarrhea, whereas animals receiving high dose rapamycins
showed toxic signs (hair loss, wound healing problems). Histological examination showed a signi®cant increase in intimal hyperplasia in
group 1 (0.03 ^ 0.01 and 0.14 ^ 0.05 mm after 30 and 60 days, respectively; P , 0:01). Rapamycins in either application or dosage had no
signi®cant effect on intimal hyperplasia. Conclusions: Local or systemic administration of rapamycins has no effect on intimal hyperplasia in
synthetic vascular grafts. In contrast, toxic signs with weight loss were observed in animals treated with high dose rapamycins, but not in
those treated with MMF. Thus, in the rat model, immunosuppresssion with rapamycins or MMF cannot be recommended for the prevention
of intimal hyperplasia in the synthetic vascular graft model. q 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Coronary and peripheral bypass operations are performed
routinely for myocardial or peripheral ischemia. The best
results are obtained with autologous arterial or venous graft
materials, like internal mammary artery and saphenous vein
grafts. However, graft material can be limited due to vein
disease or previous use of vein material. Therefore,
synthetic graft material has been used as a substitute, but
vascular grafts below 6 mm diameter have a high occlusion
rate, mainly due to graft thrombosis in the early phase and
intimal hyperplasia in the late phase [1]. Early graft throm-
bosis can be minimized with good surgical techniques, and
adequate antiplatelet or anticoagulation treatment in
patients with a good run-off. More recently, new graft mate-
rial and the surface (heparin) coating of grafts have been
shown to improve graft patency [2]. However, graft occlu-
sion due to intimal hyperplasia remains a major problem.
Several methods have been used to improve graft patency in
small vascular grafts, such as pharmacological interven-
tions, cell seeding and, more recently, tissue engineering
of synthetic grafts [3]. Immunosuppressive agents have
been used only rarely due to unwanted side-effects, but
the antiproliferative properties may reduce intimal hyper-
plasia [4±6]. Gregory and co-workers have shown that a
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high dose of rapamycins reduces intimal hyperplasia in the
rat carotid artery injury model [7,8]. Others have shown that
most immunosuppressive agents have a bene®cial effect on
intimal hyperplasia in allogenic vascular grafts [9±12]. So
far, no study has been carried out showing that rapamycins
or mycophenolate mofetil (MMF) have a bene®cial effect on
intimal proliferation and long-term patency in synthetic
vascular grafts.
2. Materials and methods
In 69 Wistar rats, an infrarenal interposition expanded
polytetra¯uoroethylene (ePTFE; Gore-tex) graft was
implanted under general anesthesia using intraperitoneal
¯uanisone (Janssen-Cilag). The operations were performed
through a midline total laparotomy using sterile and micro-
surgical techniques. After preparation of the infrarenal aorta,
clamping, resection and end-to-end single stitch (10.0 mono-
®lament), implantation was performed. The thin-walled,
Gore-tex graft had an internal diameter of 2 mm and a length
of 10 mm. The graft patency was tested manually and the
laparotomy was closed in two layers. Postoperatively, no
antiplatelet drugs or heparin therapy were given. All animals
had standard care and received normal food.
The animals were divided into three groups: control
group 1 (n  12), group 2 treated with rapamycins
(n  37), and group 3 treated with MMF (n  5). Group 2
was further subdivided according to the route of adminis-
tration and the dosage:
2a rapamycins (RAD Novartis 1.5 or 3 mg/kg per os
by gavage).
2b rapamycins (RPM Wyeth 1.5 or 3 mg/kg intraper-
itoneally).
2c rapamycin graft soaking (RPM Wyeth).
In the last group, the grafts were immersed for 24 h in a
rapamycin saline solution on an agitator at room tempera-
ture. The animals were followed daily for graft occlusion
and drug toxicity. Body weight was measured weekly.
Each group was scheduled to comprise six animals. Four
animals died perioperatively, of narcosis accident (two) and
perioperative bleeding (two), and one animal in the treat-
ment group was inadvertently placed in the long-term
control group (n  7). All of those four animals were
replaced. In addition, ®ve animals had to be euthanized
during the ®rst 2 weeks. Two for graft thrombosis and
hind leg ischemia, and three for wound problems (poor
healing and secondary dehiscence). These animals were
also replaced. Thus, a total of 69 rats were operated.
At the conclusion of the study, either after 30 or 60 days,
the animals were anesthetized and euthanized by potassium
chloride overdose, and the grafts were dissected free and
pressure perfused in situ with glutalaldehyde. The grafts
were cut longitudinally, and after hematoxylin and eosin
staining, sections were examined at the proximal and distal
anastomoses, as well as in the middle of the graft according
to the following criteria: graft patency dimensions and inti-
mal proliferation thickness, length and area, as well as a
grading score (0, none; 1, mild; 2, moderate; and 3, severe)
for intimal proliferation, thrombus formation and cellular
ingrowth. The scores were given by an experienced vascular
pathologist blinded to the treatment groups.
All animals received human care in compliance with the
European Convention on Animal Care. The study was
approved by the veterinary ethical committee.
2.1. Statistics
The results are expressed as mean values ^ 1 SEM for
®gures or mean values ^ 1 SD for tables, respectively.
Differences between proximal and distal anastomoses were
calculated using the paired t-test. Differences among the
three groups were evaluated with a one-way analysis of
variance (ANOVA). When the analysis was signi®cant, a
Kruskal±Wallis test was performed. Comparisons within
the same group were carried out with an ANOVA for repeated
measurements (Mann±Whitney Test with Bonferroni correc-
tion) using the STATA software (Santa Monica, USA).
3. Results
3.1. Survival, body weight and side-effects
Except for the four animals dying perioperatively and the
®ve animals who were euthanized during the ®rst 2 weeks
(see above), all other animals had an uneventful recovery
after the intervention.
During the follow-up, no animal died in group 1. Five
animals died in group 2, four probably related to drug
toxicity (oral RAD) and one from late thrombosis (rapa-
mycin treated graft). In group 3, one animal was eutha-
nized because of severe diarrhea. Thus, 54 animals
completed the study.
After 3 weeks of treatment, most animals in group 2,
mainly the ones treated with oral or high dose rapamycins,
developed signs of toxicity. These included appetite and
weight loss, diarrhea, hair loss, aggressivity and wound
dehiscences (Table 1).
Rats in the control group showed an increase in body
weight of about 150 g during the ®rst month and about an
equal amount during the second month. The animals of
group 2c (rapamycin graft soaking) and group 3 (MMF)
showed a similar weight increase than the control group
animals. In contrast, especially the animals of group 2a
(RAD) receiving the high dosage, showed a signi®cantly
lower weight increase at 30 and 60 days, respectively
when compared with controls (Table 1; Fig. 1A,B).
3.2. Histological evaluation (Fig. 2A,B)
Intimal hyperplasia thickness was present at both anasto-
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moses and similar in groups 1 and 2 after 30 days. The
animals of group 3 showed a higher intimal proliferation
compared with the animals treated systemically with rapa-
mycins (0.06 ^ 0.02 vs. 0.02 ^ 0.01; P , 0:01). There was
a signi®cant increase in the controls from 30 to 60 days
(0.03 ^ 0.01 vs. 0.14 ^ 0.05 mm; P , 0:01). In group 2,
there were some differences with regard to the mode of
rapamycin application and dosage, i.e. there was a trend
towards a lower intimal proliferation in animals receiving
systemic RAD per os, especially in the high dosage.
Animals treated with the high dosage RAD per os showed
a signi®cantly lower intimal thickening when compared
with control animals at 2 months (0.04 ^ 0.02 vs.
0.1 ^ 0.08; P , 0:05). In contrast, the animals of group
2c (RPM graft soaking) showed no bene®cial effect on inti-
mal proliferation. After 2 months, the animals had a similar
intimal proliferation to the controls. Intimal hyperplasia was
more pronounced at the proximal anastomosis, followed by
the distal anastomosis and the middle of the prosthesis
(Table 2; Fig. 3A,B).
Intimal hyperplasia, thrombus formation and cellular
ingrowth scores were assessed by using a score from 0 to
3 (0, none; 3, severe). The results of the intimal hyperplasia
score were similar to the measured intimal hyperplasia
thicknesses (Table 2). There was a trend towards more
thrombus formation on the inner surface of the graft in the
animals of group 2a which were treated with oral RAD. In
addition, grafts treated with rapamycins induced more
thrombus formation (group 2c; Fig. 4A,B). Cellular
ingrowth was similar to intimal hyperplasia formation and
showed some trend towards a lesser cellular ingrowth in
animals with high dose immunosuppression.
4. Discussion
Intimal hyperplasia and graft occlusion are the major
limitations for small caliber synthetic vascular grafts.
Therefore, veins and, more recently, arteries have been
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Fig. 1. Body weight changes. (A) Body weight at baseline after 30 and 60
days: animals of group 1 (controls) and group 3 (MMF) show a similar
normal weight increase during the ®rst and second months, respectively.
Animals of group 2 (rapamycins) show a signi®cantly lower weight
increase at 1 and 2 months compared with controls. (B) Body weight
after 30 and 60 days for group 2 (rapamycins) compared with controls.
Group 2c (RPM soaking) shows a similar weight increase as the controls
up to 1 month. Group 2b (RPM) has a normal weight increase at 1 month,
whereas group 2a (RAD) shows a signi®cantly reduced weight increase at
30 (P  0:01) and 60 days (P  0:005).
Table 1
Results after 3 weeks
Group n 54 Application (mg/kg BW) Survival (days) Weight change (g)a Side-effects (n) Pb
Group 1 (controls) 5 None 30 ^ 0 166 ^ 3 0/5 ±
7 None 61 ^ 0 349 ^ 12 0/7 ±
Group 2 (rapamycins) 2a 4 p.o./(1.5)c 31 ^ 0 48 ^ 6 2/4 0.073
6 p.o./(3.0)c 27 ^ 5 215 ^ 20 2/6 0.154
4 p.o./(3.0)c 56 ^ 1 67 ^ 16 4/4 0.001
2b 6 i.p./(1.5)d 30 ^ 0 176 ^ 13 2/6 0.154
6 i.p./(3.0)d 28 ^ 1 12 ^ 6 3/6 0.064
2c 5 Soakingd 32 ^ 1 146 ^ 14 0/5 ±
6 Soakingd 62 ^ 2 267 ^ 5 0/6 ±
Group 3 (MMF) 5 p.o./(40)e 31 ^ 0 171 ^ 17 5/5f 0.053
a Signi®cances are shown on Fig. 1.
b Side-effects (x 2 to controls).
c RAD Novartis.
d Rapamycin Wyeth.
e MMF.
f Diarrhea.
used for cardiovascular bypass surgery, but a limited avail-
ability of graft material has led to the use of complex anasto-
moses in bypass techniques, such as the use of
gastroepiploic, radial and mammary arteries.
The need for synthetic graft material for small bypass
grafts is increasing dramatically, especially for the second
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Fig. 2. Histological sections of the ePTFE graft anastomosed to the infra-
renal aorta (hematoxylin and eosin). (A) Shows very little reaction and a 2±
3 layer thick intimal hyperplasia proliferation in the vicinity of the proximal
anastomosis. The rest of the prosthesis is free of pseudo-intima (group 2A at
1 month). (B) Proximal anastomosis with severe intimal hyperplasia reac-
tion on the endoluminal side (group 1, 60 days).
Table 2
Results after 2 months
Group n 54 Application
(mg/kg BW)
Survival (days) Intimal hyperplasia (0±3) Pd
Proximal anastomosis Mid-prosthesis Distal anastomosis
Group 1 (controls) 5 None 30 ^ 0 1 ^ 0 0 ^ 0 0 ^ 0 0.000
7 None 61 ^ 0 2 ^ 0.4 0.4 ^ 0.2 0.8 ^ 0.4 0.089
Group 2 (rapamycins) 2a 4 p.o./(1.5)a 31 ^ 0 1 ^ 0 0 ^ 0 0.3 ^ 0.3 0.029
6 p.o./(3.0)a 27 ^ 5 0.5 ^ 0.3 0 ^ 0 0.3 ^ 0.2 0.371
4 p.o./(3.0)a 56 ^ 1 1.3 ^ 0.5 0 ^ 0 0.8 ^ 0.3 0.196
2b 6 i.p./(1.5)b 30 ^ 0 1.5 ^ 0.3 0 ^ 0 0.2 ^ 0.2 0.001
6 i.p./(3.0)b 28 ^ 1 0.8 ^ 0.3 0.2 ^ 0.2 0.3 ^ 0.2 0.102
2c 5 Soakingb 32 ^ 1 1 ^ 0 0 ^ 0 0.4 ^ 0.2 0.035
6 Soakingb 62 ^ 2 1.5 ^ 0.3 0.7 ^ 0.2 1.2 ^ 0.2 0.233
Group 3 (MMF) 5 p.o./(40)c 31 ^ 0 1.4 ^ 0.4 0 ^ 0 0.4 ^ 0.2 0.071
a RAD Novartis.
b Rapamycin Wyeth.
c MMF.
d P, paired t-test proximal vs. distal anastomosis.
Fig. 3. Intimal thickness. (A) Results of intimal thickness at 30 and 60 days
for groups 1, 2 and 3. There is a signi®cant increase in intimal thickness
between animals surviving 30 and 60 days (groups 1 and 2; P , 0:01).
Group 3 shows a signi®cantly higher (P , 0:01) value than the animals
of group 2 after 30 days (P , 0:01). (B) The subgroups of rapamycin
treated animals after 1 month in comparison with controls at 1 month are
shown. Group 2a (RAD) shows a trend towards less intimal thickness than
2b or 2c.
or third bypass operation or for patients with inadequate
autologous graft material. The purpose of the present study
was to assess the effect of immunosuppressive drugs for the
prevention of neointimal hyperplasia in small vascular
synthetic grafts.
The results were assessed at 30 and 60 days, since it has
been shown in rat models that the strongest mediator and
growth-factor activity happens during the ®rst 2±3 weeks
[13].
Intimal proliferation increased with time and was more
pronounced at the anastomoses than in the center of the
synthetic vascular grafts (Table 2). Rapamycin treated grafts
showed less intimal proliferation than control grafts
(.0.05), but due to the large variations, this difference did
not reach statistical signi®cance. No effect was seen with
MFF treated rats when compared with controls (Fig. 3A).
Due to the high dose, rapamycins were associated with
weight loss and signs of toxicity (diarrhea, loss of hair and
wound healing problems). However, no clear effect on
patency was found. There was an increased thrombus
formation, especially in the high dose rapamycin groups
(P , 0:01; Fig. 4B). This is probably due to the diminished
endothelialization provoked by the high dose of immuno-
suppression [14±16].
In conclusion, high dose immunosuppression reduces
mildly intimal proliferation, especially at the anastomosis
in synthetic vascular grafts in the rat. This bene®cial effect is
linked with increased drug toxicity. Thus, these side-effects
and the lack of a signi®cant reduction in intimal hyperplasia
limit the use of systemically administered immunosuppres-
sive drugs for the prevention of intimal hyperplasia and
graft occlusion in small caliber synthetic vascular grafts.
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Appendix A. Conference discussion
Dr M. Murtra (Barcelona, Spain): Could I ask if all animals survived the
experiment, and if you have any controls after performing surgery to make
sure that all grafts were patent? Did you have 100% survival of all animals,
because it's a pretty tough operation?
Dr Walpoth: The randomization was done after the surgery. So the
animals who would have a technical problem would be replaced. So we
started off with six animals in each group, and during the course, some
animals have been euthanized, especially the animal with severe side-
effects. That's why the groups had different numbers of animals.
Dr J.R.L. Hamilton (Newcastle-upon-Tyne, UK): Why did you choose
these drugs particularly?
Dr Walpoth: Because it has been shown that mainly rapamycin has the
strongest inhibition on smooth muscle cell and endothelial cell prolifera-
tion.
Dr Murtra: Do you think in the future there will be any clinical applica-
tion? And if so, for how long would you recommend to keep the treatment ±
3 months, 6 months?
Dr Walpoth: As I said in my conclusion, I don't think it's the way to go
clinically. Most reports in the literature have been using allotransplanted
grafts requiring immunosuppression anyhow, and then they have shown
that there is a signi®cant reduction of intimal hyperplasia.
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